News and Events

Strike Pharma has been granted a patent in Japan (JP 2021-529122), protecting the company’s core ADAC technology

The project is financed by the European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS program BIO-X Accelerate

Scientists from Strike Pharma presented two scientific posters demonstrating progress in the preclinical development of STRIKE2001-KRAS and in the use of the ADAC technology platform for drug cargo delivery.

FyoniBio to present data at PEGS Boston 2023

Chief Scientific Officer, Associate Professor Sara Mangsbo, presented some of the latest data demonstrating progress in the development of the ADAC technology platform for precision cancer immunotherapy.

Research to be supported by Cancerfonden, one of Sweden’s largest financiers of cancer research

Joacim Elmén appointed as Director, CMC

Agreement covers Cell Line Development for a novel bi-specific therapeutic mAb

Dr. Sara Mangsbo acknowledged for entrepreneurship and her contribution to Swedish life science industry

Niclas Stiernholm elected as Chairman of the Board

Appoints Lindvi Gudmunsdotter as Director, Non-Clinical Development

CD40 agonistic, bispecific antibody candidates developed using ADAC technology ensure T-cell activation

New data demonstrates proof of concept for ADAC technology platform

Efforts now focus on bringing first candidate to clinical trials and further development of ADAC technology platform

Swedish immuno-oncology newcomer STRIKE Pharma raises SEK 10 million for development of individualized solid tumour therapy.

STRIKE Pharma appoints industry veteran Mårten Winge as new CEO